Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 11,970

Document Document Title
WO/2018/104856A1
A process of obtaining a purified geometric isomer of an unsaturated macrocyclic compound is disclosed herein. The process is effected by contacting an ion exchange medium comprising silver ions with a mixture comprising at least one geo...  
WO/2018/100137A1
The invention relates to nucleoside triphosphate and nucleoside triphosphate analogue prodrugs. It is an object of the present invention to provide improved nucleoside triphosphate or nucleoside triphosphate analogue prodrugs. To achieve...  
WO/2018/099946A1
The present invention relates to novel bicyclic nucleosides and oligomers prepared therefrom. In particular, the present invention relates to a compound of formula (I), wherein one of T1 and T2 is OR1 or OR2; and the other of T1 and T2 i...  
WO/2018/101431A1
The purpose of the present invention is to provide a 2-O-α-D-glycosyl-L-ascorbic acid composition which has excellent moisturizing properties and excellent skin wettability. The present invention relates to: a 2-O-α-D-maltosyl-L-ascorb...  
WO/2018/096831A1
Provided are a novel nucleoside derivative or salt thereof, polynucleotide synthesis reagent, polynucleotide production method, polynucleotide, and binding nucleic acid molecule production method. This nucleoside derivative or salt there...  
WO/2018/092107A1
Novel anti-Viral and anti-Cancer molecule containing nucleobase or its derivatives or its analogues attached to an Ascorbic Acid molecule or its derivatives or its analogues with or without an oxygen bond in-between.  
WO/2018/094148A1
Compounds that modulate the conversion of AMP to adenosine by 5'- nucleotidase, ecto, and compositions containing the compounds and methods for synthesizing the compounds, are described herein. The use of such compounds and compositions ...  
WO/2018/091542A1
The present invention relates to Compounds of Formula (I) or Formula (II) or a pharmaceutically acceptable salt, solvate or enantiomer thereof, wherein A, B, R1, R2, R3, R4, Q and V are as defined herein. The present invention also relat...  
WO/2018/093717A1
The present invention features compositions and methods for the treatment of HCV infection. In one embodiment, the compositions of the invention comprise (1) Compound 1 or a pharmaceutically acceptable salt thereof, and (2) Compound 2a o...  
WO/2018/089830A1
The present disclosure provides methods of making nicotinoyl riboside compounds or derivatives of formula (I): wherein X", Z 1, Z2, n, R 1, R2, R3, R4, R5, R6,,R7, and R 8 are described herein, reduced analogs thereof, modified derivativ...  
WO/2018/085833A2
The disclosure is directed to compounds of Formula I, Formula II, and Formula III [Formulas should be inserted here]. Methods of their use and preparation are also described.  
WO/2018/085307A1
The present invention provides prodrugs of clofarabine. The compounds of the invention have formula (I), or a pharmaceutically acceptable salt thereof, wherein R1 is H or -C(=0)-X-R3 and R2 is H or -C(=0)-Y-R4, wherein X and Y are each i...  
WO/2018/081785A1
An antiviral compound of the following formula (I) is provided or a salt or a pharmaceutically acceptable salt thereof, where B is a naturally occurring or non-naturally occurring base; R1 is a C2-C14 alkyl group; X is O, S, CH=CH (cis) ...  
WO/2018/079503A1
Provided is a simple and practical method for removing iron ions, as a method for purifying P1,P4-di(uridine 5'-)tetraphosphate from a solution that contains iron ions. This method for purifying P1,P4-di(uridine 5'-)tetraphosphate by rem...  
WO/2018/071531A1
The disclosure provides linked purine pterin compounds of Formula I that are novel inhibitors of HPPK, a kinase responsible for an essential step in the biosynthesis of folic acid. (Formula I) The variables, e.g., A1-A3, R1-R4, B1-B2, an...  
WO/2018/070543A1
The purpose of the present invention is to provide a method for producing a phosphoramidite suitable for nucleic acid production (synthesis) with high efficiency and high purity. A phosphoramidite which allows for efficient nucleic acid ...  
WO/2018/067241A1
The present invention relates to macroheterocyclic nucleoside derivatives and their analogues, production and use thereof. These compounds are the prodrugs for treating viral and cancerous diseases and are inhibitors of HCV NS5B polymera...  
WO/2018/066690A1
The purpose of the present invention is to provide: crystals of cytidine diphosphate choline which contain no methanol and have improved powder properties; and a process for producing the crystals. The process according to the present in...  
WO/2018/064078A1
Apparatus and means by which a polysaccharide or other heterogeneous polymer is concatenated with a nucleic acid polymer that is captured by a primer on a polymerase tethered to a bead trapped by a nanopore. The translocation of the nano...  
WO/2018/059214A1
Provided are compounds affecting SAICAR synthesis, and applications. On the basis of existing protein structure data and small molecule structure data, calculations and analysis are performed using software to screen and obtain compounds...  
WO/2018/060323A1
The present invention relates to compounds of general formula (I), wherein the groups R1, R2 and R3 are defined as in claim 1, which have valuable pharmacological properties, particularly are modulators of STING.  
WO/2018/051581A1
Provided are a novel nucleoside derivative or a salt thereof, a reagent for synthesizing a polynucleotide, a method for producing a polynucleotide, a polynucleotide, and a method for producing a binding nucleic acid molecule. This nucleo...  
WO/2018/051903A1
[Problem] To provide a compound having excellent antibacterial properties and a compound having an excellent ability to enhance antibacterial properties of another antibacterial agent. [Solution] A sugar derivative having an antibacteria...  
WO/2018/052063A1
Provided are a novel nucleoside derivative or a salt thereof, a reagent for synthesizing a polynucleotide, a method for producing a polynucleotide, a polynucleotide, and a method for producing a binding nucleic acid molecule. This nucleo...  
WO/2018/051580A1
Provided are a novel nucleoside derivative or a salt thereof, a reagent for synthesizing a polynucleotide, a method for producing a polynucleotide, a polynucleotide, and a method for producing a binding nucleic acid molecule. This nucleo...  
WO/2018/049535A1
Nucleoside analogues that can be used as anticancer or antiviral agents are presented. These compounds are nucleoside and/or nucleotide prodrugs. In particular, the subject matter relates to nucleoside analogues comprising a tetrahydrofu...  
WO/2018/049534A1
Nucleoside and nucleotide analogues that can be used as cardioprotective agents are provided. The nucleosides and nucleotide analogues comprise tetrahydrofuranyl or tetrahydrothienyl moieties with quaternary stereogenic all-carbon center...  
WO/2018/052064A1
Provided are a novel nucleoside derivative or a salt thereof, a reagent for synthesizing a polynucleotide, a method for producing a polynucleotide, a polynucleotide, and a method for producing a binding nucleic acid molecule. This nucleo...  
WO/2018/045997A1
The present application falls within the field of drug synthesis, and relates to a method for preparing 2-fluoro-2-methyldeoxynucleoside as an intermediate of Sofosbuvir. In particular, the present application provides a method for prepa...  
WO/2018/047715A1
The purpose of the present invention is to provide: crystals of β-nicotinamide mononucleotide (NMN) which have excellent storage stability; and a production process therefor. According to the present invention, crystals of NMN can be pr...  
WO/2018/047909A1
Disclosed is a purine nucleoside derivative represented by formula (Ia) or the like. In the formula, each of X1 and X2 independently represents a nitrogen atom, -CH= or -CR2= (wherein R2 represents an alkyl group); Ar represents an optio...  
WO/2018/048937A1
The use of described compounds or pharmaceutically acceptable salts or compositions thereof for the treatment of a host infected with an RNA virus other than HCV, or other disorder more fully described herein.  
WO/2018/049145A1
The invention relates to novel heterocyclic compounds and pharmaceutical preparations thereof. The invention further relates to methods of treating or preventing cancer using the novel heterocyclic compounds of the invention.  
WO/2018/045317A1
Disclosed herein are oligonucleotides, such as nucleic acid inhibitor molecules, having a 4'-phosphate analog and methods of using the same, for example, to modulate the expression of a target gene in a cell. The phosphate analogs are bo...  
WO/2018/041942A1
Embodiments of the invention are directed to new polymer linked multimeric guanosine-3', 5'-cyclic monophosphate (cGMP) analogues that modulate the cGMP-signaling system, preferably having activating properties, and more preferably being...  
WO/2018/042841A1
A SAMe-containing material having a high SAMe content can be obtained by a method which comprises: a heating/dissolving step for supplying water and brown sugar to a culture tank and dissolving the brown sugar by heating; a culture step ...  
WO/2018/033639A1
The present invention is directed to lactones of the following structural formula for use as precursors of NAD, and their use as nutritional supplements.  
WO/2018/033492A1
The invention proves an oligonucleotide comprising one or more carboxylated 2'- amino-LNA nucleotide units. The invention also provides a method of transfecting cells with the oligonucleotide, a method of treating a human or animal by th...  
WO/2018/034987A1
Methods and compounds are disclosed for irreversibly inhibiting a DNA repair enzyme that possesses lyase activity.  
WO/2018/033593A1
The present invention relates to novel compounds for the treatment of Hepatitis C.  
WO/2018/033719A1
The invention provides compounds for use in a method of treating and/or preventing a bacterial infection in a human or non-human mammal, said method comprising administration of said compound in combination with (either simultaneously, s...  
WO/2018/031818A3
Disclosed herein are nucleotide analogs, methods of synthesizing nucleotide analogs and methods of treating diseases and/or conditions such as a Picornaviridae and/or Flaviviridae viral infections with one or more nucleotide analogs.  
WO/2018/028494A1
A gemcitabine ProTide hypoxic-activated prodrug and a use thereof in the preparation of a medicament for treating tumors. The general structural formula thereof is formula (A), wherein: one of R1 and R2 is a hypoxic-activated group of -C...  
WO/2018/031818A2
Disclosed herein are nucleotide analogs, methods of synthesizing nucleotide analogs and methods of treating diseases and/or conditions such as a Picornaviridae and/or Flaviviridae viral infections with one or more nucleotide analogs.  
WO/2018/024265A1
Substituted heteropentadieno-pyrrolopyrimidine ribonucleosides of general formula (I), where R is selected from the group comprising furan-2-yl, furan-3-yl, benzofuran-2-yl, methylsulfanyl, methoxy, amino, dimethylamino, methyl or chloro...  
WO/2018/023205A1
A purification method for nicotinamide mononucleotide, relating to a method for purifying an NMN crude product obtained via a biocatalysis method. The purpose of the present method is to solve the problems in existing NMN purification me...  
WO/2018/019748A1
The invention relates to a compound of formula (I) wherein R2 and R4 are joined and together form a group, such a -CH2O-. The compound of formula (I) can be used in the manufacture of 5'S-LNA oligonucleotides as antisense drugs.  
WO/2018/019188A1
Provided are a crystal form A of a nucleoside phosphoramidate prodrug as shown in formula I and a preparation method therefor. The crystal form A at least has an X-ray powder diffraction (XRPD) pattern with peaks at the 2θ angles of 6.9...  
WO/2018/015821A1
The present invention relates to an improved, commercially viable and industrially advantageous process for the preparation of Sofosbuvir. The present invention involves use of reagents that are less expensive, easier to handle and eco-f...  
WO/2018/014111A1
There is provided methods, compositions and treatment regimens for treating cancer, or for inhibiting metastasis/recurrence of cancer in a patient using 1) a primary cancer treatment such as chemotherapy, and 2) within 12 to 120 hours po...  

Matches 1 - 50 out of 11,970